Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 127 Matches

Osimertinib_V14R1_AstraZeneca_20190717

Model Files Publication

Compound file from publication: Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. Pilla Reddy V, Walker M, Sharma P, Ballard P, Vishwanathan K (2018). CPT Pharmacometrics Systems Pharmacolology. doi: 10.1002/psp4.12289.

Search Score: 1

Tramadol_V14R1_JohnsonandJohnson_20151029

Model Files Publication

V12 R1 compound file built to simulate adult Human PK and pediatric PK. Supplied file is for V14 R1. “Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data” in Pharm Res January 2015, Volume 32, Issue 1, pp 260-274 http://link.springer.com/article/10.1007%2Fs11095-014-1460-x “Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.” in AAPSJ November 2015, Volume 17, Issue 6, pp 1376-1387 http://link.springer.com/article/10.1208%2Fs12248-015-9803-z

Search Score: 1

Entecavir_V15R1_USFDA_20170810

Model Files Publication

Entecavir compound file in healthy volunteers. Evaluation of the effect of renal impairment on PK of OAT substrates. NOTE: file has predicted Vss of 0.98 L/kg. Table 1 value is 0.9 L/kg. http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full

Search Score: 1

Fenebrutinib_RES_V21R1_Simcyp_20230615

Model Files Publication

Prepared: June 2023 The RES-Fenebrutinib_V21 model has been developed primarily as an inhibitor of hepatic OATP1B1 and OATP1B3, and intestinal BCRP using the New GI physiology in Simcyp V21 with altered GI tract population inputs that became default in V22. The RES-Fenebrutinib is verified as solution formulation for 100mg SD, 200mg SD, and 200mg BID. The Rosuvastatin DDI is using a 200 mg BID dosing for Fenebrutinib. Example workspaces for the Fenebrutinib PK and the DDI with Rosuvastatin are attached. The BCRP component of Rosuvastatin (V21 using the New GI physiology) was optimised using Eltrombopag and then verified with other BCRP-Inhibitors available on the members area or within the Simcyp Simulator, see attached ‘BCRP-Inhibitor V21’ document for details.

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Osimertinib_V14R1_AstraZeneca_20190717

Tramadol_V14R1_JohnsonandJohnson_20151029

Entecavir_V15R1_USFDA_20170810

Fenebrutinib_RES_V21R1_Simcyp_20230615

Your Privacy